Katarzyna Latusek-Kotyczka

Mrs. Katarzyna Latusek-Kotyczka

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Life
Verified
Journal Article
Open access
PDF file
RWRafał Wiench
Rafał Wiench
JFJakub Fiegler-Rudol
Jakub Fiegler-Rudol
KLKatarzyna Latusek-Kotyczka
Katarzyna Latusek-Kotyczka
KBKatarzyna Brus-Sawczuk
Katarzyna Brus-Sawczuk
HFHanna Fiegler
Hanna Fiegler
DSDariusz Skaba
Dariusz Skaba
Photodynamic therapy (PDT) using indocyanine green (ICG) has gained attention as an adjunctive treatment for periodontitis due to its antimicrobial and anti-inflammatory properties and its ability to penetrate deep periodontal tissues via near-infrared light activation. We aimed to evaluate the clinical and microbiological efficacy of ICG-mediated PDT as an adjunct to conventional periodontal therapy in patients with periodontitis based on data from randomized controlled trials (RCTs). A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted to identify randomized controlled trials (RCTs) exclusively investigating ICG-PDT in periodontitis based on predefined eligibility criteria. Studies were selected based on predefined inclusion criteria, and methodological quality was assessed using a 14-point scoring system. Data were extracted on clinical outcomes (e.g., probing depth, clinical attachment level) and microbiological changes. Sixteen RCTs met the inclusion criteria. Most studies reported improvements in probing depth, clinical attachment level, and microbial reduction following ICG-aPDT; however, some trials found no significant differences compared to control groups. These discrepancies may be attributable to variations in laser settings, ICG concentration, treatment frequency, or initial disease severity. Microbiological benefits included significant reductions in key periodontal pathogens. The therapy was well tolerated, with no adverse effects reported. However, variability in treatment protocols and limited long-term follow-up restricted the ability to draw definitive conclusions. ICG-mediated PDT is a promising, safe, and effective adjunct in periodontal therapy. Future trials should aim for protocol standardization and long-term outcome assessment to strengthen clinical guidance.

7 November 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AWAleksandra Warakomska
Aleksandra Warakomska
KMKępa Małgorzata
Kępa Małgorzata
JFJakub Fiegler-Rudol
Jakub Fiegler-Rudol
KLKatarzyna Latusek-Kotyczka
Katarzyna Latusek-Kotyczka
DSDariusz Skaba
Dariusz Skaba
RWRafał Wiench
Rafał Wiench
Background: Candida albicans is increasingly recognized in peri-implantitis due to its capacity to form resilient biofilms on implant surfaces, limiting treatment success. Antimicrobial photodynamic therapy (aPDT) may offer a non-invasive adjunct by leveraging photosensitizer activation to produce reactive oxygen species that disrupt microbial cells. This in vitro study assessed the antifungal efficacy of QroxB2, a dual-photosensitizer containing riboflavin and curcumin, activated by 450 nm blue light against C. albicans biofilms on titanium implants. Methods: C. albicans biofilms were formed on 63 titanium implants and randomly assigned to nine groups (n = 7): untreated control (GC), chlorhexidine (CHX), riboflavin (RIB), curcumin (CUR), QroxB2 (QBX), laser only (L), and three photodynamic therapy groups combining laser irradiation with each photosensitizer (L + RIB, L + CUR, L + QBX). Treatments were followed by colony-forming unit (CFU) enumeration. Results: The L + QBX group showed the strongest antifungal effect, achieving a 94% reduction in fungal load, with median CFU counts decreasing from 49,000 in the untreated control to 2800 CFU/mL. CHX eradicated all viable cells (0 CFU/mL). Among photosensitizer-only groups, QBX produced a moderate reduction (median 21,800 CFU/mL), whereas laser irradiation alone (L) exhibited no meaningful antifungal activity, with median counts comparable to the untreated control (49,000 CFU/mL). Conclusions: QroxB2-mediated aPDT achieved a significant reduction in Candida albicans colony-forming units on implant surfaces. While not as potent as chlorhexidine, this light-activated, biocompatible approach may serve as a complementary tool in managing peri-implant fungal infections. Clinical validation is warranted.

1 January 2023 in Undersea and Hyperbaric Medicine
Verified
Journal Article
Closed access
KLKatarzyna Latusek-Kotyczka
Katarzyna Latusek-Kotyczka
ASAdrianna Słotwińska
Adrianna Słotwińska
AMAnna Michniak
Anna Michniak
BOBoguslawa Orzechowska-Wylęgała
Boguslawa Orzechowska-Wylęgała
Background and objective: Hyperbaric oxygen (HBO2) has been the subject of research in many areas of dentistry. HBO2 seems to be a useable, additional treatment method. However, there are still no certain conclusions and clear guidelines for procedures. The aim of the study was to collect current literature assessing the use of hyperbaric oxygen therapy in the treatment of periodontitis. Materials and Methods: The following review was performed using medical databases Medline via PubMed and Google Scholar. The review presents articles which assess the effect of hyperbaric oxygen therapy in combination with non-surgical scaling and root planing (SRP) in patients with periodontitis as an adjunctive method to standard protocols. Results: There are potentially plausible mechanisms by which HBO2 could be beneficial. Further well -designed science research and clinical trials are needed. Due to a small body of literature, differences in methodology and observation periods the data are not sufficient for statistical analysis. Conclusion: The use of HBO2 seems to be reasonable as an adjunct method of the periodontitis treat-ment. However, authors of this literature review could not unambiguously state that hyperbaric oxygen therapy could be commonly recommended as a potential method of periodontitis treatment. It is essential to develop consistent protocols for the procedure and further research in this area.

7 May 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
KLKatarzyna Latusek-Kotyczka
Katarzyna Latusek-Kotyczka
ASAdrianna Słotwińska
Adrianna Słotwińska
AWAleksandra Warakomska
Aleksandra Warakomska
MKMagdalena Kubicka-Musiał
Magdalena Kubicka-Musiał
RWRafał Wiench
Rafał Wiench
BOBogusława Ewa Orzechowska-Wylęgała
Bogusława Ewa Orzechowska-Wylęgała
Periodontitis is a chronic inflammatory disease with multifactorial aetiology. The relationship between periodontal disease and systemic diseases such as diabetes, obesity, metabolic syndrome, atherosclerotic, cardiovascular disease, and cognitive disorders has been the subject of many studies. The purpose of this study was to evaluate the effectiveness of hyperbaric oxygen therapy on periodontal health in patients suffering from periodontitis and type 2 diabetes. The study was conducted with 14 patients. A total of 369 periodontal pockets in the study group and 431 in the control group were examined. For further analysis, the pockets were classified as moderately deep (4–5 mm) and deep (≥6 mm). All patients received standard non-surgical treatment: scaling and root planing (SRP). Additionally, a series of 30 hyperbaric chamber sessions was carried out in the study group. The following parameters were compared between groups: PD (probing depth), CAL (clinical attachment level), and BOP (bleeding on probing). The results of the study showed significantly better results in terms of PD reduction and CAL gain in the study group in comparison to the control group. Both groups showed a reduction in BOP (bleeding on probing) after treatment. The use of hyperbaric oxygen therapy seems to have considerable benefits in patients with type 2 diabetes.

26 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SNStanisław Niemczyk
Stanisław Niemczyk
WNWojciech Niemczyk
Wojciech Niemczyk
KBKatarzyna Kamila Bąk-Drabik
Katarzyna Kamila Bąk-Drabik
KLKatarzyna Latusek-Kotyczka
Katarzyna Latusek-Kotyczka
AZAnna Zawilska
Anna Zawilska
Marzena DominiakMarzena Dominiak
Marzena Dominiak
Background/Objectives: The rising global prevalence of inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, has resulted in an increase in the number of affected patients requiring dental care. The heightened risk of Clostridioides difficile infection (CDI) in IBD patients, particularly when exposed to commonly used dental antibiotics, is attributable to their altered gut microbiota and frequent immunosuppressive therapy. The objective of this review is to evaluate current antibiotic strategies for dental management in IBD and to identify safe and effective alternatives that minimise CDI risk. Methods: A narrative review was conducted in accordance with the SANRA guidelines. A comprehensive analysis of literature sourced from PubMed, Embase, Scopus, and Google Scholar was conducted. Results: The available evidence suggests that first- and second-line dental antibiotics—amoxicillin, ampicillin, and clindamycin—carry the highest risk of CDI. In contrast, metronidazole, which exhibits a comparable antimicrobial spectrum, has been shown to possess significantly reduced CDI potential and minimal disruption of gut microbiota. The utilisation of emerging local delivery systems, such as platelet-rich fibrin (PRF), has the potential to further reduce systemic antibiotic exposure. The adjunctive use of probiotics, prebiotics and synbiotics has been demonstrated to have the capacity to maintain microbial balance during therapy. Conclusions: Tailored, microbiome-conscious antibiotic strategies are essential in dental management of IBD patients. Further clinical research is needed to develop evidence-based guidelines and validate promising adjunctive approaches.